未分化甲状腺癌分子机制和治疗进展

摘要
图/表
参考文献(0)
相关文章 (1)

全文: PDF (9324 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要未分化甲状腺癌（anaplastic thyroid carcinoma，ATC）是一种高度恶性上皮性肿瘤，占所有甲状腺癌死亡病例的14%~39%。迄今为止，ATC尚无标准的有效治疗方案，目前常规治疗以外科切除和放化疗为主，其1年生存率仅为10%~20%。基于ATC基因组学和蛋白质组学的致病分子机制的深入研究，揭示了ATC个体化治疗更多潜在靶点，为ATC个体化精准治疗提供了策略依据，有望提高ATC的治疗效果，改善预后。本文重点针对ATC致病的分子机制以及个体化精准治疗进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈宝定1
	赵双双1
	陈延玮1
	王珂珂1
	张政1
	袁国跃2

关键词 ：未分化甲状腺癌, 分子机制, 靶点, 个体化, 精准治疗

收稿日期: 2021-01-21

基金资助:国家自然科学基金资助项目（81370889）

通讯作者: 袁国跃（通讯作者），主任医师，博士生导师，E-mail：yuanguoyue@ujs.edu.cn

作者简介: 陈宝定（1978—），男，博士，主任医师；赵双双（共同第一作者），主治医师；

引用本文:

陈宝定1，赵双双1，陈延玮1，王珂珂1，张政1，袁国跃2. 未分化甲状腺癌分子机制和治疗进展[J]. 江苏大学学报:医学版, 2021, 31(02): 93-100.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2021/V31/I02/93

［1］Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies \[J\]. Nat Rev Endocrinol, 2017, 13（11）: 644-660.

\[2\]Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25year singleinstitution experience \[J\]. Ann Surg Oncol, 2014, 21（5）: 1665-1670.

\[3\]Jiao C, Li L, Zhang P, et al. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radiotherapeutic response by regulating the Smad7TGFβ pathway \[J\]. Cell Death Differ, 2020, 27（2）: 497-508.

\[4\]Ma Y, Cang S, Li G, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression \[J\]. J Cell Physiol, 2019, 234（12）: 22260-22271.

\[5\]Hao Z, Wang P. Lenvatinib in management of solid tumors \[J\]. Oncologist, 2020, 25（2）: e302-e310.

\[6\]Capdevila J, Wirth LJ, Ernst T, et al. PD1 blockade in anaplastic thyroid carcinoma \[J\]. J Clin Oncol, 2020, 38（23）: 2620-2627.

\[7\]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 \[J\]. CA Cancer J Clin, 2019, 69（1）: 7-34.

\[8\]Haddad RI, Nasr C, Bischoff L, et al. Nccn guidelines insights: thyroid carcinoma, version 2.2018 \[J\]. J Natl Compr Canc Netw, 2018, 16（12）: 1429-1440.

\[9\]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries \[J\]. CA Cancer J Clin, 2018, 68（6）: 394-424.

\[10\]Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective \[J\]. Mol Cancer, 2018, 17（1）: 154.

\[11\]Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid \[J\]. Cancer, 1978, 41（6）: 2267-2275.

\[12\]Nel CJ, Van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases \[J\]. Mayo Clin Proc, 1985, 60（1）: 51-58.

\[13\]Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment \[J\]. J Oncol, 2011, 2011: 542358.

\[14\]Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies \[J\]. Clin Oncol （R Coll Radiol）, 2010, 22（6）: 486-497.

\[15\]Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers \[J\]. J Clin Invest, 2016, 126（3）: 1052-1066.

\[16\]Amin MB, Greene FL, Edge SB, et al. The eighth edition ajcc cancer staging manual: continuing to build a bridge from a populationbased to a more “personalized” approach to cancer staging \[J\]. CA Cancer J Clin, 2017, 67（2）: 93-99.

\[17\]Lamartina L, Grani G, Arvat E, et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect （ITCO#2） \[J\]. Endocr Relat Cancer, 2018, 25（3）: L7-L11.

\[18\]周东辉, 钭赉振, 朱小桦,等. 未分化甲状腺癌的靶向和免疫治疗研究进展 \[J\]. 浙江医学，2020，42（18）：1903-1908.

\[19\]Ahmed S, Ghazarian MP, Cabanillas ME, et al. Imaging of anaplastic thyroid carcinoma \[J\]. AJNR Am J Neuroradiol, 2018, 39（3）: 547-551.

\[20\]Cabanillas ME, Mcfadden DG, Durante C. Thyroid cancer \[J\]. Lancet, 2016, 388（10061）: 2783-2795.

\[21\]DeekenDraisey A, Yang GY, Gao J, et al. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular singleinstitution study \[J\]. Hum Pathol, 2018, 82: 140-148.

\[22\]Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the national cancer data base \[J\]. Cancer, 2017, 123（9）: 1653-1661.

\[23\]Kwon J, Kim BH, Jung HW, et al. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and metaanalysis \[J\]. Eur J Cancer, 2016, 59: 34-45.

\[24\]Amaral M, Afonso RA, Gaspar MM, et al. Anaplastic thyroid cancer: how far can we go? \[J\]. Excli J, 2020, 19: 800-812.

\[25\]Melo M, Da Rocha AG, Vinagre J, et al. Tert promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas \[J\]. J Clin Endocrinol Metab, 2014, 99（5）: E754-765.

\[26\]Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma \[J\]. Cell, 2014, 159（3）: 676-690.

\[27\]Kunstman JW, Juhlin CC, Goh G, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via wholeexome sequencing \[J\]. Hum Mol Genet, 2015, 24（8）: 2318-2329.

\[28\]Jeon MJ, Chun SM, Kim D, et al. Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF（V600E） mutationprevalent area \[J\]. Thyroid, 2016, 26（5）: 683-690.

\[29\]Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene \[J\]. Cancer Res, 2011, 71（13）: 4403-4411.

\[30\]Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 （IDH1） mutations in thyroid cancer \[J\]. Biochem Biophys Res Commun, 2010, 393（3）: 555-559.

\[31\]Zhu G, Xie L, Miller D. Expression of microRNAs in thyroid carcinoma \[J\]. Methods Mol Biol, 2017, 1617: 261-280.

\[32\]Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways \[J\]. Cancer Cell, 2016, 29（4）: 452-463.

\[33\]Zhou Q, Chen J, Feng J, et al. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroidstimulating hormone receptor （TSHR） \[J\]. Tumour Biol, 2016, 37（3）: 3105-3113.

\[34\]Wang XM, Liu Y, Fan YX, et al. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway \[J\]. Cancer Biol Ther, 2018, 19（7）: 590-597.

\[35\]Huang JK, Ma L, Song WH, et al. LncRNAMALAT1 promotes angiogenesis of thyroid cancer by modulating tumorassociated macrophage FGF2 protein secretion \[J\]. J Cell Biochem, 2017, 118（12）: 4821-4830.

\[36\]Borbone E, Troncone G, Ferraro A, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas \[J\]. J Clin Endocrinol Metab, 2011, 96（4）: 1029-1038.

\[37\]Gunda V, Cogdill AP, Bernasconi MJ, et al. Potential role of 5aza2′deoxycytidine induced MAGEA4 expression in immunotherapy for anaplastic thyroid cancer \[J\]. Surgery, 2013, 154（6）: 1456-1462.

\[38\]Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways \[J\]. J Clin Endocrinol Metab, 2010, 95（2）: 820-828.

\[39\]Mcfadden DG, Vernon A, Santiago PM, et al. P53 constrains progression to anaplastic thyroid carcinoma in a Brafmutant mouse model of papillary thyroid cancer \[J\]. Proc Natl Acad Sci U S A, 2014, 111（16）: E1600-E1609.

\[40\]Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAFinduced thyroid cancer is associated with epithelialmesenchymal transition requiring concomitant MAP kinase and TGFβ signaling \[J\]. Oncogene, 2011, 30（28）: 3153-3162.

\[41\]Li LC, Jayaram S, Ganesh L, et al. Knockdown of MADD and cFLIP overcomes resistance to TRAILinduced apoptosis in ovarian cancer cells \[J\]. Am J Obstet Gynecol, 2011, 205（4）: 362 e312-e325.

\[42\]Milosevic Z, Pesic M, Stankovic T, et al. Targeting RASMAPKERK and PI3KAKTmTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma \[J\]. Transl Res, 2014, 164（5）: 411-423.

\[43\]Byeon HK, Na HJ, Yang YJ, et al. CMetmediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF（V600E） mutant thyroid cancer to BRAF inhibition \[J\]. Mol Carcinog, 2016, 55（11）: 1678-1687.

\[44\]Zhong Z, Hu Z, Jiang Y, et al. Interleukin11 promotes epithelialmesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/AKT/GSK3β signaling pathway activation \[J\]. Oncotarget, 2016, 7（37）: 59652-59663.

\[45\]The Lancet. Breast cancer targeted therapy: successes and challenges \[J\]. Lancet, 2017, 389（10087）: 2350.

\[46\]Lieu CH, Corcoran RB, Overman MJ. Integrating biomarkers and targeted therapy into colorectal cancer management \[J\]. Am Soc Clin Oncol Educ Book, 2019, 39: 207-215.

\[47\]Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments \[J\]. Lancet, 2017, 389（10066）: 299-311.

\[48\]Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer \[J\]. N Engl J Med, 2013, 368（7）: 684-685.

\[49\]Xin Y, Bai Y, Jiang X, et al. Sulforaphane prevents angiotensin Ⅱinduced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK3β/Fyn pathway \[J\]. Redox Biol, 2018, 15: 405-417.

\[50\]Baldini E, D′armiento M, Ulisse S. A new aurora in anaplastic thyroid cancer therapy \[J\]. Int J Endocrinol, 2014, 2014: 816430.

\[51\]Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma \[J\]. Thyroid, 2014, 24（2）: 232-240.

\[52\]Catalano MG, Pugliese M, Gallo M, et al. Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase Ⅱ/Ⅲ trial \[J\]. Int J Endocrinol, 2016, 2016: 2930414.

\[53\]Mehta A, Zhang L, Boufraqech M, et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer \[J\]. Endocr Relat Cancer, 2015, 22（3）: 319-329.

\[54\]Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer \[J\]. Endocrine, 2012, 42（3）: 637-646.

\[55\]French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers \[J\]. Lancet Diabetes Endocrinol, 2017, 5（6）: 469-481.

\[56\]Caillou B, Talbot M, Weyemi U, et al. Tumorassociated macrophages （TAMS） form an interconnected cellular supportive network in anaplastic thyroid carcinoma \[J\]. PLoS One, 2011, 6（7）: e22567.

\[57\]Bastman JJ, Serracino HS, Zhu Y, et al. Tumorinfiltrating T cells and the PD1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer \[J\]. J Clin Endocrinol Metab, 2016, 101（7）: 2863-2873.

\[58\]Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD1 and PDL1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study \[J\]. J Clin Endocrinol Metab, 2017, 102（6）: 1943-1950.

\[59\]Brauner E, Gunda V, Vanden Borre P, et al. Combining braf inhibitor and anti PDL1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer \[J\]. Oncotarget, 2016, 7（13）: 17194-17211.

\[60\]Kollipara R, Schneider B, Radovich M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer \[J\]. Oncologist, 2017, 22（10）: 1149-1151.

\[61\]Zwaenepoel K, Jacobs J, De Meulenaere A, et al. Cd70 and PDL1 in anaplastic thyroid cancerpromising targets for immunotherapy \[J\]. Histopathology, 2017, 71（3）: 357-365.

\[62\]Zhu L, Li XJ, Kalimuthu S, et al. Natural killer cell （NK92MI）based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model \[J\]. Front Immunol, 2017, 8: 816.

\[63\]Allegri L, Baldan F, Mio C, et al. Effects of BP14, a novel cyclindependent kinase inhibitor, on anaplastic thyroid cancer cells \[J\]. Oncol Rep, 2016, 35（4）: 2413-2418.

\[64\]Abdulghani J, Gokare P, Gallant JN, et al. Sorafenib and quinacrine target antiapoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer （ATC） \[J\]. Clin Cancer Res, 2016, 22（24）: 6192-6203.

\[65\]Ball DW, Jin N, Xue P, et al. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer \[J\]. Oncol Rep, 2015, 34（5）: 2319-2324.

\[66\]Vanden Borre P, Gunda V, Mcfadden DG, et al. Combined BRAF（V600E）and SRCinhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer \[J\]. Oncotarget, 2014, 5（12）: 3996-4010.

\[67\]Chin LH, Hsu SP, Zhong WB, et al. Combined treatment with troglitazone and lovastatin inhibited epidermal growth factorinduced migration through the downregulation of cysteinerich protein 61 in human anaplastic thyroid cancer cells \[J\]. PLoS One, 2015, 10（3）: e0118674.

\[68\]IngesonCarlsson C, MartinezMonleon A, Nilsson M. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF（V600E） mutant thyroid cancer cells in 2D and 3D culture \[J\]. Exp Cell Res, 2015, 338（2）: 127-135.